GlassScriptPhysician profile
Douglas Conrad
NPI 1780605378
$1,872.04
in general payments reported to CMS, 2019-2025
14 companies · $1,539 in 2025
The $1,539 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $53.06 · 2021: $13.89 · 2023: $122 · 2025: $1,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,500 · Food and Beverage: $143 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,500.00 |
| Food and Beverage | $142.87 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $1,500.00 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $168.90 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.18 | 2023 | Ofev |
| Insmed, INC. | $67.61 | 2019-2025 | Brinsupri, Arikayce |
| Genzyme Corporation | $26.46 | 2023 | |
| Nestle Healthcare Nutrition INC. | $13.89 | 2021 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Conrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.